An official website of the United States government
A Study of a New PET Scanner in Patients with Cancer
Trial Status: active
This trial tests the effects of breath holding, how the radiotracer given moves through the body and how the timing of the scan works for a whole body PET scan for completing diagnostic imaging for patients with cancer. A PET scan is a procedure in which a small amount of radioactive glucose (sugar) is injected into a vein, and a scanner is used to make detailed, computerized pictures of areas inside the body where the glucose is taken up. Because cancer cells often take up more glucose than normal cells, the pictures can be used to find cancer cells in the body. Breath holding while undergoing can reduce motion blur (when an image looks less sharp because the body is moving, such as during breathing) and produce clearer images of lesions. Giving a radiotracer before the scan and completing an additional dynamic scan can show how the radiotracer moves into and out of tumors and healthy organs over time and completing a scan after the planned scan may show may make tumor tissue easier to see because of washout (when the radiotracer leaves healthy tissues over time). By examining these different imaging techniques, researchers may determine the best way to use the whole body PET scan for completing diagnostic imaging for patients with cancer.
Inclusion Criteria
OBJECTIVE 1: Patients with histologically-confirmed non-small cell lung carcinoma (NSCLC) with a single or multiple lung nodules
OBJECTIVE 1: Patients who are undergoing a planned PET-CT scan at main campus of Memorial Sloan Kettering (MSK)
OBJECTIVE 1: Patients must be ≥ 18 years old
OBJECTIVE 2: Patients with disease within the chest, abdomen or pelvis, who could benefit from visualizing the pharmacokinetics of radiotracer uptake within all disease sites simultaneously
OBJECTIVE 2: We will focus on patients with metastatic prostate or head and neck cancer.
* Patients with prostate cancer who are undergoing a 68Ga-PSMA or 18F-FDG scan at the main campus of MSK.
* Patients with head and neck cancer who are undergoing a 18F-FDG scan at the main campus of MSK
OBJECTIVE 2: Patients must be ≥ 18 years old
OBJECTIVE 3: Patients with histologically-confirmed cancer from all three groups (lung cancer, head and neck cancer, prostate cancer)
OBJECTIVE 3: Patients who are undergoing an 68Ga-PSMA or 18F-FDG or an [18F]-fluormisonidazole PET-CT scan at the main campus of MSK
OBJECTIVE 3: Patients willing to return to the Molecular Imaging and Therapy (MITS) clinic for late imaging session between 2 to 6 hours after the PET radiotracer injection. (In current practice, FDG is imaged between 1 and 1.5 hours post injection, and FMISO is imaged between 2.5 and 3 hours post injection)
OBJECTIVE 3: Patients must be ≥ 18 years old
Exclusion Criteria
Patients who suffer from claustrophobia
Women who are pregnant or breast-feeding
Patients < 18 years of age
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT07690917.
Locations matching your search criteria
United States
New Jersey
Basking Ridge
Memorial Sloan Kettering Basking Ridge
Status: Active
Contact: Heiko Schoder
Phone: 212-639-8001
Middletown
Memorial Sloan Kettering Monmouth
Status: Active
Contact: Heiko Schoder
Phone: 212-639-8001
Montvale
Memorial Sloan Kettering Bergen
Status: Active
Contact: Heiko Schoder
Phone: 212-639-8001
New York
Commack
Memorial Sloan Kettering Commack
Status: Active
Contact: Heiko Schoder
Phone: 212-639-8001
New York
Memorial Sloan Kettering Cancer Center
Status: Active
Contact: Heiko Schoder
Phone: 212-639-8001
Uniondale
Memorial Sloan Kettering Nassau
Status: Active
Contact: Heiko Schoder
Phone: 212-639-8001
West Harrison
Memorial Sloan Kettering Westchester
Status: Active
Contact: Heiko Schoder
Phone: 212-639-8001
PRIMARY OBJECTIVES:
I. To perform an fludeoxyglucose (FDG) positron emission tomography (PET) scan under Deep Inspiration Breath Hold (DIBH) in addition to the planned PET-computed tomography (CT) exam.
II. To reconstruct dynamic data to generate pharmacokinetic profiles of the PET radiotracer for tumors and normal organs.
III. To perform a late scan after several physical half-lives of the PET radiotracer.
OUTLINE: Patients are assigned to 1 of 3 aims.
AIM 1: Patients receive fludeoxyglucose F 18 (18F-FDG) intravenously (IV) and undergo standard of care PET-CT scan. Patients then undergo CT scan followed by a PET scan using the deep inspiration breath hold technique.
AIM 2: Patients undergo CT scan then patients receive 18F-FDG or gallium Ga 68 gozetotide (68Ga PSMA) IV and undergo PET scan. At specified scan time post-injection, usually 60-80 minutes, patients undergo standard of care PET-CT scan.
AIM 3: Patients receive 18F-FDG IV or 18F-Fluoromisonidazole (18F-FMISO) IV or 68Ga PSMA IV. At specified scan time post-injection, usually 60-80 minutes, patients undergo standard of care PET-CT scan. Patients then return later and undergo an additional PET scan.
Trial PhaseNo phase specified
Trial Typediagnostic
Lead OrganizationMemorial Sloan Kettering Cancer Center
